Description & Pharmacodynamics 5-Amino-1MQ is a selective inhibitor of NNMT, an enzyme involved in regulating cellular methylation balance and energy metabolism
Cycle structure: the common research community cycle is 8 to 12 weeks on, then 4 to 6 weeks off
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A Category 2 Update, April 22, 2026
Some people develop itching only on their first injection, while others experience it sporadically across multiple doses
Unlike BPC-157, which is often described as more localized, TB-500 is thought to act systemically , supporting broader recovery functions such as: Peptides for muscle recovery Circulation and vascular growth support Flexibility and mobility during rehabilitation Why Combine BPC-157 and TB-500
Each vial contains 5mg of TB-500 (Thymosin Beta-4 analogue) and 5mg of BPC-157 (Body Protection Compound-157), co-lyophilised into a single vial for research convenience